title: Current immunochemotherapy strategies in follicular lymphoma.
abstract: Nowadays, there is no consensus about the best treatment for patients with follicular lymphoma (FL) in differing situations. In frontline treatment, a watchful waiting policy remains a good option if the patient has no risk criteria; the role of rituximab is under investigation in this setting. In patients needing therapy, immunotherapy or immunochemotherapy are the best options; although it has not been established which chemotherapy, including cyclophosphamide, vincristine, and prednisone (CVP); cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP); fludarabine, or bendamustine combinations, is the best partner for rituximab. Following frontline treatment, recent and still unpublished data strongly suggest a role for maintenance with rituximab, instead of observation only. At relapse, immunochemotherapy is the standard induction approach. The role of maintenance after induction is well established, although comparative studies with autologous stem-cell transplantation (ASCT) or other combinations are warranted. The role of ASCT in this setting is a matter of discussion. Other monoclonal antibodies, as well as vaccines and other immunotherapies, are currently under investigation. Finally, allogeneic transplantation should be reserved for a very select group of young high-risk patients in the setting of clinical trials.
authors.affiliation: Department of Hematology, Hospital Clinic, Barcelona, Spain.
authors.forename: Eva
authors.initials: E
authors.lastname: Giné
authors.forename: Gonzalo
authors.initials: G
authors.lastname: Gutiérrez-García
authors.forename: Armando
authors.initials: A
authors.lastname: López-Guillermo
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D000069461:Bendamustine Hydrochloride; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008224:Lymphoma, Follicular / Q000276:immunology / Q000628:therapy*; D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D016499:Radioimmunotherapy; D000069283:Rituximab; D033581:Stem Cell Transplantation; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D009588:Nitrogen Mustard Compounds; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D000069461:Bendamustine Hydrochloride; D014740:Vidarabine; C024352:fludarabine; D011241:Prednisone